Dr. Yonghe Li

Southern Research Institute, USA

Email: [email protected]

Qualifications

1998    Ph.D., Biochemistry, James Cook University of North Queensland, Australia

1988 M.Sc., Radiobiology, School of Graduate Studies, Shanghai Medical University, China

1985 B.Sc., Pharmacology, School of Pharmacy, Shanghai Medical University, China

Publications (Selected)

1. Arend, R. C., Londoño-Joshi, A. I., Gangrade, A., Katre, A. A., Kurpad, C., Li, Y. H., ... Buchsbaum, D. J. (2016). Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. Oncotarget, 7(52), 86803–86815.
2. Arend, R. C., Londoño-Joshi, A. I., Samant, R. S., Li, Y. H., Conner, M., Hidalgo, B., ... Buchsbaum, D. J. (2014). Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer. Gynecologic Oncology, 134(1), 112–120.
3. Arend, R. C., Gangrade, A., Haygood, C. L. W., Kurpad, C., Metge, B. J., Samant, R. S., ... Buchsbaum, D. J. (2015). Overcoming platinum resistance in ovarian cancer with niclosamide. Clinical Cancer Research, 21(16_Suppl), THER-1402.
4. Chen, Y., Xiao, M. M., Mo, Y. Q., Ma, J. L., Han, Y. M., Li, Q., ... Xu, B. (2024). Nuclear porcupine mediates XRCC6/Ku70 S-palmitoylation in the DNA damage response. Experimental Hematology & Oncology, 13(1), 109.
5. Haygood, C. L. W., Arend, R. C., Li, P. K., Li, Y. H., Kurpad, C., Gangrade, A., ... Buchsbaum, D. (2014). Niclosamide analogs for treatment of ovarian cancer. Cancer Research, 74(19_Suppl), 4677.
6. Li, N., Chen, X., Zhu, B., Ramírez-Alcántara, V., Canzoneri, J. C., Lee, K., ... Piazza, G. A. (2015). Suppression of β-catenin/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10. Oncotarget, 6(29), 27403–27415.
7. Li, N., Lee, K., Xi, Y. G., Zhu, B., Gary, B. D., Ramírez-Alcántara, V., ... Piazza, G. A. (2014). Phosphodiesterase 10A: A novel target for selective inhibition of colon tumor cell growth and Wnt/β-catenin signaling. Cancer Research, 74(19_Suppl), 1773.
8. Li, Y. H., Li, P. K., Roberts, M. J., Arend, R. C., Samant, R. S., & Buchsbaum, D. J. (2014). Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. Cancer Letters, 349(1), 8–14.
9. Li, Y. H., Lu, W. Y., Chen, D. Q., Boohaker, R. J., Zhai, L., Padmalayam, I., ... Zhang, W. (2015). KIFC1 is a novel potential therapeutic target for breast cancer. Cancer Biology & Therapy, 16(9), 1316–1322.
10. Li, Y. H., Lu, W. Y., & King, T. D. (2016). Regulation of Wnt/β-catenin signaling by Wnt co-receptor LRP6 in colorectal cancer cells. Cancer Research, 76(14_Suppl), 4600.
11. Li, Y. H., Lu, W. Y., Saini, S. K., Moukha-Chafiq, O., Pathak, V., & Ananthan, S. (2016). Identification of quinazoline compounds as novel potent inhibitors of Wnt/β-catenin signaling in colorectal cancer cells. Oncotarget, 7(10), 11263–11270.
12. Li, Y. H., Oliver, P. G., Lu, W. Y., Pathak, V., Augelli-Szafran, C. E., Buchsbaum, D. J., & Suto, M. J. (2017). Discovery of a series of benzimidazoles as potent Wnt/β-catenin signaling inhibitors in colorectal cancer cells. Cancer Research, 77(13_Suppl), 5173.
13. Li, Y. H., Oliver, P. G., Lu, W. Y., Pathak, V., Sridharan, S., Augelli-Szafran, C. E., ... Suto, M. J. (2017). RETRACTED: SRI36160 is a specific inhibitor of Wnt/β-catenin signaling in human pancreatic and colorectal cancer cells. Cancer Letters, 389, 41–48.
14. Li, Y. H., Oliver, P. G., Lu, W. Y., Pathak, V., Sridharan, S., Augelli-Szafran, C. E., ... Suto, M. J. (2018). RETRACTION: SRI36160 is a specific inhibitor of Wnt/β-catenin signaling in human pancreatic and colorectal cancer cells. Cancer Letters, 422, 131.
15. Li, Y. H., Yin, Y. L., He, Y., He, K., & Li, J. D. (2022). SOS1 regulates HCC cell epithelial-mesenchymal transition via the PI3K/AKT/mTOR pathway. Biochemical and Biophysical Research Communications, 637, 161–169.
16. Lu, W. Y., & Li, Y. H. (2014). Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells. Journal of Cellular Biochemistry, 115(10), 1799–1807.
17. Lu, W. Y., Lin, C. H., & Li, Y. H. (2014). Rottlerin induces Wnt co-receptor LRP6 degradation and suppresses both Wnt/β-catenin and mTORC1 signaling in prostate and breast cancer cells. Cellular Signalling, 26(6), 1303–1309.
18. Ma, J. L., Han, S. X., Sui, X., Lu, W. Y., Li, Y. H., & Xu, B. (2017). Mutations of SPOP, FOXA1 and IDH1 are associated with prostate cancer metastasis and biochemical outcomes. Cancer Research, 77(13_Suppl), 2702.
19. Ma, J. L., Lu, W. Y., Chen, D. Q., Xu, B., & Li, Y. H. (2017). Role of Wnt co-receptor LRP6 in triple negative breast cancer cell migration and invasion. Journal of Cellular Biochemistry, 118(9), 2968–2976.
20. Mathew, B., Hobrath, J. V., Lu, W. Y., Li, Y. H., & Reynolds, R. C. (2017). Synthesis and preliminary assessment of the anticancer and Wnt/β-catenin inhibitory activity of small amide libraries of fenamates and profens. Medicinal Chemistry Research, 26(11), 3038–3045.

Profile Details
https://www.researchgate.net/profile/Yonghe-Li-2

WOS ResearcherID: OUN-4101-2025